Live/On Demand9月22日（金）13:40～14:55　第14会場

座長：

三森　功士

九州大・病院・別府病院・外科

演者：

茂田　啓介

慶應義塾大学医学部泌尿器科学教室

三橋　惇志

徳島大学大学院　呼吸器・膠原病内科学分野

中野　倫孝

スタンフォード大学　医学部

中村　能章

国立がん研究センター東病院

小栁　友理子

愛知県がんセンターがん予防研究分野

Live/On Demand9月22日（金）14:55～16:10　第14会場

座長：

北林　一生

国立がん研セ・研

演者：

松野　悠介

国立がん研セ・研・ゲノム安定性制御

山岸　良多

大阪公立大・院医・病態生理学

熊谷　尚悟

国立がん研究センター研究所細胞情報学分野

渡邉　達郎

佐賀大・創薬科学共同研究講座

柴　綾

筑波大・医・診断病理

クローン性造血がもたらす血液がん・固形がん発症のパラダイムシフト

Live/On Demand9月21日（木）9:00～11:30　第1会場

座長：

坂田（柳元）　麻実子

筑波大・医・血液内科

Ravi Majeti

Stanford University

演者：

Ravi Majeti

Stanford University

佐伯　龍之介

京都大学　医学研究科　腫瘍生物学講座

Lucy A. Godley

Division of Hematology/Oncology, Robert H. Lurie Cancer Center, Northwestern Univ

坂田（柳元）　麻実子

筑波大・医・血液内科

企画趣旨・ねらい

The discovery of clonal hematopoiesis (CH) has innovated the novel scientific world in both blood and solid cancers. CH is a state in which hematopoietic stem cells acquire somatic mutations in genes involved in epigenetic pathways, splicing machineries, DNA repair, and as so forth during aging. CH serves as a predisposing state for various age-related diseases, including lifestyle diseases and cancers. Remarkably, in patients of solid and blood cancers harboring CH, the immune cells derived from CH are infiltrated into cancer tissues and serve as a niche to support cancer cells. Furthermore, CH is important in cancer management: Eventual detection of CH by panel sequencing, especially liquid biopsies may influence the choice of treatment options. CH affects side effects of immune therapies and cytotoxic drugs in cancer therapies. Paradoxically, cancer therapies shape the mutational profiles of CH, and induce secondary blood cancers originated from CH. In this symposium, we will focus on the recent progress in the roles of CH in cancer development and management, targeting both blood and solid cancers. The deeper insight into CH will lead to the better managements of cancers.

RNA Splicing as a New Hallmark of Cancer

Live/On Demand9月23日（土）9:00～11:30　第1会場

座長：

吉見　昭秀

国立がん研究センター がんRNA研究分野

Stanley Lee

Translational Science&Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

演者：

吉見　昭秀

国立がん研究センター がんRNA研究分野

Yoseph Barash

Department of Genetics, Perelman School of Medicine, University of Pennsylvania

鈴木　啓道

国がん・研究所・脳腫瘍連携研究分野

Stanley Lee

Translational Science&Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

企画趣旨・ねらい

Dysregulated RNA splicing is a molecular feature that characterizes almost all tumor types. Cancer-associated splicing alterations arise from both mutations affecting splice sites as cis-acting factors and recurrent mutations or altered expression of trans-acting factors governing splicing catalysis and regulation. These aberrant splicing events promote tumorigenesis via diverse mechanisms, contributing to increased cell proliferation, decreased apoptosis, enhanced migration and metastatic potential, resistance to chemotherapy and evasion of immune surveillance. Recent studies have identified specific cancer-associated isoforms that play critical roles in cancer cell transformation and growth and demonstrated the therapeutic benefits of correcting or otherwise antagonizing such cancer-associated mRNA isoforms. In addition, clinical-grade small molecules that modulate or inhibit RNA splicing have been developed as promising anticancer therapeutics. This JCA-AACR Joint Symposium presents cutting-edge research on aberrant RNA splicing in cancer and discuss the outstanding questions and challenges that should be addressed to translate these findings into the clinic. As far as the organizers know, this will be the first big session on RNA splicing in the history of JCA annual meetings, adding RNA splicing as a new hallmark in cancer.

Young Plenary Symposium

Live/On Demand9月21日（木）13:40～15:40　第1会場

座長：

河野　隆志

国立がん研セ・がんゲノム情報管理セ

西川　博嘉

国立がん研セ・研・腫瘍免疫研究分野

演者：

板橋　耕太

国立がん研究センター　腫瘍免疫研究分野

The-Wei Wang

Division of Cancer Cell Biology, IMSUT／Division of Cancer and Senescence Biology, KU CRI

安部　佳亮

筑波大学　医学医療系　血液内科／筑波大学附属病院　血液内科

太田　悠木

慶應義塾大学医学部医化学教室

小谷　大輔

国がん東・消化管内科

企画趣旨・ねらい

The first author (a young researcher) of an outstanding original paper will be selected by the program committee members to give an oral presentation on the paper and its subsequent development at the main venue of the conference.

日本発抗がん剤開発物語

Live/On Demand9月21日（木）16:20～18:20　第1会場

座長：

間野　博行

国立がん研セ・研

眞島　喜幸

日本希少がん患者会ネットワーク

横井　晃

エーザイ（株）

演者：

阿部　有生

第一三共・研究イノベーション推進部

高橋　建

協和キリン・メディカルアフェアーズ

船橋　泰博

エーザイ Inc. DHBL MDドメイン

吉田　隆雄

小野薬品工業　オンコロジー研究センター

長澤　崇

ファイザーR&D合同会社・医薬開発部門

企画趣旨・ねらい

抗がん剤のシーズ開発から最終的な製剤承認に至るまでのステップには様々なハードルが存在します。日本発のシーズ、あるいは日本が開発の中心となって国際的に成功した代表的な抗がん剤の開発において、どのステップに苦労があり、それをいかに乗り越えて、どのような喜びがあったのかを、開発した会社の方々に実体験をご紹介いただきます。他では聴けない創薬のリアルを体感してください。

創薬シーズ大集合

Live/On Demand9月22日（金）9:00～10:30　第1会場

座長：

都賀　稚香

国立がん研セ・研

天野　慎介

（一社）全国がん患者団体連合会

吉田　卓

アステラス製薬・イムノオンコロジー

講演者：

塚本　一成

アステラス製薬株式会社

演者：

池田　豊

筑波大学　数理物質系

中村　孝司

北大院薬

高田　護

千葉大学　医学部　臓器制御外科学

寺島　裕也

東京理科大学　生命医科学研究所

評価者：

森　聖寿

協和キリン株式会社

吉松　賢太郎

株式会社凜研究所

藤田　修平

アステラス製薬株式会社

大堀　誠

東京大学協創プラットフォーム開発株式会社

企画趣旨・ねらい

がん研究に携わる科学者で，自らの発見（シーズ）が，将来の治療そして患者さんの生活により良い変革をもたらすことを期待しない方はいないと思います。
一方で，「どのように」という自問自答をした途端に五里霧中となることが，一度ならずともあるのではないでしょうか。
治療や薬の研究開発は，そのフェーズに応じた専門家を巻き込む必要があります。ただし研究者も各専門家も，すべてフェーズの知識を有しているわけではありません。
だからこそ「シーズのあって欲しい姿（Profile）」をチームで共有し，そこを目指すために各専門性を発揮することが重要です。
シーズがinnovativeであればあるほど，無限の可能性を語れるのは研究者です。その可能性の中から，患者さんが必要とするゴールに導くためのエクササイズをしませんか？
創薬シーズ大集合では秘密保持契約無しで開示できるシーズを募集します。ぜひ様々な段階のシーズを応募ください。
シーズに期待する患者さんの視点や，そこに向かうためには何が必要かを企業の視点を知ることで，今後の研究開発ロードマップを具体化する機会となることを期待しています。

AMED合同シンポジウム:AMEDがん研究が果たすミッションと今後の課題　-次の10年のAMEDがん研究を見据えて-

Live/On Demand9月22日（金）10:30～11:30　第1会場

座長：

宮園　浩平

東京大

直江　知樹

名古屋医療セ

演者：

福田　悠平

日本医療研究開発機構

大島　正伸

金沢大・がん研・腫瘍遺伝学

仁平　新一

（一社）オンコロジー学術研究フォーラム

大津　敦

国がん東・病院長

佐谷　秀行

藤田医大・がん医療研究センター

企画趣旨・ねらい

Based on the 10-year strategy for cancer research, AMED has supported many academic studies since its establishment.
Cancer research projects of AMED has been conducted through two core projects to advance research & development (R&D) from the early stage of actual drug development (target discovery) to the late stage (clinical development). These projects are based on researchers' originality and ingenuity, and AMED, PS/PO, and “support organizations” work together to establish a system to manage progress and provide support according to the milestones of each research project.
In the second phase of AMED, a new project promotion system has been established based on drug discovery modalities, and R&D is proceeding toward the creation and exit phase of highly novel seeds through collaboration with or utilization of other related programs. These efforts are expected to make further progress toward the practical application of academic seeds.
In the lectures, we will introduce the research policy from the entrance to the exit of cancer research supported by AMED and the expectations for each research topics from the PS/PO of the two core projects. We hope that this symposium will lead to discussion of the cancer research issues that AMED should address in the next decade will be discussed, and that many researchers will participate in AMED projects in the future.

Woman Scientist Plenary Symposium

Live/On Demand9月22日（金）13:40～15:40　第1会場

座長：

間野　博行

国立がん研セ・研

大谷　直子

大阪公立大・院医

演者：

柴　綾

筑波大・医・診断病理学

前田　優香

国がん・研・腫瘍免疫

水野　林

京都大・医生物学研究所／京都大・医学研究科・婦人科学産科学

小川　亜希子

東北大加齢研　モドミクス医学分野／熊本大　生命科学研究部　眼科学

芳野　聖子

名古屋大学・医院・分子腫瘍学

企画趣旨・ねらい

The first author (a female researcher) of an outstanding original paper will be selected by the program committee members to give an oral presentation regarding her paper and subsequent developments of the research project. The presentation will be held at the main conference venue. We hope this symposium will encourage young women researchers.

Science Translational Medicine

Live/On Demand9月22日（金）7:50～8:40　第1会場

座長：

河野　隆志

国立がん研セ・C-CAT

演者：

Courtney S. Malo

Science Translational Medicine

Nature

Live/On Demand9月22日（金）11:50～12:40　第1会場

座長：

西川　博嘉

国立がん研セ・研・腫瘍免疫研究分野

演者：

Zoltan Fehervari

Springer Nature

Cancer Discovery

Live/On Demand9月23日（土）7:50～8:40　第1会場

座長：

間野　博行

国立がん研セ・研・所長

演者：

Robert Paul Kruger

American Association for Cancer Research

3学会合同シンポジウム（日本癌学会+日本免疫学会+日本がん免疫学会）
腫瘍免疫学から考えるがん免疫療法の未来

Live/On Demand9月21日（木）9:00～11:30　第15会場

座長：

藤井　眞一郎

理研・生命医科学研究・免疫細胞治療／理研・創薬医療技術基盤・aAVC基盤

鳥越　俊彦

札幌医大・医・病理学第一講座

西川　博嘉

国立がん研セ・研・腫瘍免疫研究分野

演者：

藤井　眞一郎

理研・生命医科学研究・免疫細胞治療／理研・創薬医療技術基盤・aAVC基盤

前田　優香

国がん・研・腫瘍免疫

金関　貴幸

札幌医大・病理学第一講座／同・免疫プロテオゲノミクス共同研究拠点

Wouter Scheper

Dept of Molecular Oncology and Immunology, The Netherlands Cancer Institute

Miriam Merad

Icahn School of Medicine at Mount Sinai

Catherine J. Wu

Dana-Farber Cancer Institute, Harvard Medical School

企画趣旨・ねらい

With the successes of immune checkpoint inhibitors, immunotherapy has become one of the standard strategies in cancer therapies for various types of cancer. However, the clinical efficacy is still limited, and more than half of patients failed to respond to cancer immunotherapies. Therefore, it is urgently required to identify predictive biomarkers that can stratify responders from non-responders and to develop more effective cancer immunotherapeutic strategies based on basic research. Thus, in this joint symposium of 3 academic societies (JCA, JSI, and JACI), we will address various obstacles to successful cancer immunotherapy; Understanding immunosuppressive components in the tumor microenvironment which hamper the induction of effective antitumor immunity is a key issue for the future of cancer immunotherapy tailored to each patient. We hope our discussion will help progress toward the next generation of cancer immunotherapy.

2学会合同シンポジウム（日本癌学会＋日本薬学会）
抗がん剤モダリティ研究の最前線

Live/On Demand9月21日（木）13:40～16:10　第2会場

座長：

一條　秀憲

東京大・院薬

楠原　洋之

東京大・院薬

演者：

浦野　泰照

東京大・院薬／東京大・院医

山次　健三

千葉大院薬

秋田　英万

東北大・薬・薬物送達

山田　勇磨

北海道大学　大学院薬学研究院／JST 創発的研究支援事業

向井　英史

長崎大・院・医歯薬・医薬品情報学

青木　淳賢

東大院・薬・衛生化学

企画趣旨・ねらい

Various treatment modalities have been developed to overcome cancer. The modalities now include genetically modified T cells, oncolytic viruses, and vaccines to strengthen the immune response against cancer. This symposium is planned to introduce emerging pharmaceutical research aimed at developing novel modalities for cancer diagnosis and therapy and share the vision of future directions with the audience. Organic chemistry has advanced the creation of novel functional molecules designed as theranostic probes that aid diagnosis and therapy, and efficient delivery of treatments (small molecules and RNA/DNA) to their target cells and even intracellular target organelles (mitochondria). The presentations will also shed light on the challenges faced in investigating live bacteria as a new treatment modality and signal transduction elicited by lipid mediators in tumor immunity. The six lines of research are expected to be able to address the public’s expectations regarding new approaches to cancer therapy.

2学会合同シンポジウム（日本癌学会＋日本生化学会）
代謝研究が拓くがんの新たな理解

Live/On Demand9月22日（金）9:00～11:30　第5会場

座長：

水島　昇

東京大・院医・分子生物学

本橋　ほづみ

東北大・加齢研・遺伝子発現制御分野

演者：

小松　雅明

順大・医・生理2

関根　弘樹

東北大学・加齢研・遺伝子発現制御

Christine Chio

Columbia University Medical Center

有田　誠

慶應大・薬・代謝生理化学／慶應大・WPI-Bio2Q／理研・生命医セ・メタボローム／横市大・院生命医・代謝エピゲノム科学

河岡　慎平

東北大学・加齢医学研究所／京都大学・医生物学研究所

Liron Barpeled

Cancer Center, MGH

企画趣旨・ねらい

The development of new analytical techniques has enabled comprehensive analysis of metabolites, identification of new metabolites, quantification of metabolites, and tracer analysis using stable isotopes, and metabolism research in biochemistry has been very active. While nucleic acids and proteins located upstream of the central dogma can be comprehensively investigated to some extent using certain analytical methods, metabolites at the bottom of the dogma are extremely diverse and cannot be detected unless analytical methods are tailored to the properties of individual metabolites. We believe that there are still many important metabolites that we are unaware of. We also expect that there are metabolites whose dynamics we are unaware of and which play important regulatory roles. In this symposium, up-and-coming young researchers from Japan and abroad will present their latest research results on the characteristics of cancer that have been revealed by metabolic studies and their potential therapeutic applications.

2学会合同シンポジウム（日本癌学会＋日本病理学会）
がんの病理組織を用いた空間解析最前線

Live/On Demand9月22日（金）9:00～11:30　第16会場

座長：

谷田部　恭

国立がん・研究所・分子病理

田中　伸哉

北大・医・腫瘍病理／北大・化学反応創成研

演者：

谷田部　恭

国立がん・研究所・分子病理

田中　伸哉

北大・医・腫瘍病理／北大・化学反応創成研

花田　雄一

アステラス製薬イムノオンコロジー

Giaccone Giuseppe

鈴木　絢子

東大・新領域

岡本　康司

帝京大学・先端総合研究機構

企画趣旨・ねらい

This symposium, in collaboration with the Japanese Society of Pathology (JSP), focuses on the spatial analysis of cancer tissue, which has recently been introduced in the research field. To date, single-cell analysis has revealed specific cancer cell clusters, together with various cellular components comprising the microenvironment with infiltrating immune cells. In addition, techniques for spatial transcriptome analysis, including Visium, Xenium, CosMx, and MERSCOPE, have been developed, resulting in the acceleration of further understanding of cancer tissues. Thus, collaboration between pathologists with a profound understanding of cancer tissues and basic researchers actively facilitates scRNA-seq, and spatial transcriptome analysis may provide novel insights into cancer research. In this symposium, an initial overview and expectations are followed by the recent advancements in cancer research using these techniques. We hope that this collaborative symposium of the JCA-JSP will create an epoch of new cancer research for a precise understanding of the spatiotemporal construction of cancer tissues, contributing to the discovery of aspects of clonal evolution of cancers and new therapeutic targets.

3学会合同シンポジウム（日本癌学会・日本人類遺伝学会・日本遺伝カウンセリング学会）
網羅的がんゲノム医療時代の遺伝性腫瘍診療と遺伝カウンセリング

Live/On Demand9月22日（金）9:00～11:30　第17会場

座長：

平田　真

国立がん研セ・中央病院

吉田　玲子

(公財)がん研・研・がんゲノム研究部／昭和大　臨床ゲノム研究所

櫻井　晃洋

札幌医科大

演者：

山本　英喜

岡山大・院・医歯薬・臨床遺伝子医療学／岡山大・病院・臨床遺伝子診療科／姫路赤十字病院・遺伝診療部／広島市民病院・遺伝子診療科／中央西日本遺伝性腫瘍コホート

吉田　玲子

(公財)がん研・研・がんゲノム研究部／昭和大　臨床ゲノム研究所

池上　政周

東京都立駒込病院　骨軟部腫瘍科

桃沢　幸秀

理研・生命医科学セ・基盤技術開発研

植木　有紗

がん研有明病院　臨床遺伝医療部

有田　美和

筑波大学附属病院・遺伝診療部

企画趣旨・ねらい

Hereditary tumor syndromes (HTS) are also entering a new era, both in their clinical management and research, ushered mainly by the high-throughput sequencing technologies and various informational resources. Multi-gene panels have been offered increasingly in oncology clinical practice, and whole-genome analyses for cancer and intractable diseases are underway as a national project. Genetic counseling is a core of every aspect of clinical care of HTS, from diagnosis and treatment to prevention, and approach to at-risk relatives. Genetic counseling is also required to be updated and ready for the New Era with comprehensive germline genomic profiling. Even if we focus our attention on genetic diagnosis, the emerging impacts will be at least three-fold: 1) expansion of the landscape of genetic predisposition to cancer to encompass moderate risk variants, modifiers and polygenic influences, 2) increasing chance to encounter secondary findings, including non-neoplastic diseases and 3) paucity of data on genotype-phenotype relationships for variants detected in the absence of classical HTS phenotypes. The New Era demands multidisciplinary collaborations beyond the current level, and the Symposium has been organized as a joint session by 3 societies, The Japan Society of Human Genetics, The Japanese Society for Genetic Counseling and The Japanese Cancer Association. We expect and welcome active and open, inspiring discussions on genetic and genomic medicine for HTS.

がん研究と分子生物学の邂逅：髙久史麿先生記念シンポジウム

Live/On Demand9月23日（土）9:00～11:30　第3会場

座長：

宮園　浩平

東京大・医・応用病理学／理研・生命医科学研究センター

石川　冬木

京都大

演者：

宮園　浩平

東京大・医・応用病理学／理研・生命医科学研究センター

坂田（柳元）　麻実子

筑波大・医・血液内科

小川　誠司

京都大学・大学院医学研究科・腫瘍生物学

石川　冬木

京都大学・学術研究展開センター

間野　博行

国立がん研究センター研究所

企画趣旨・ねらい

The current cancer therapeutics rely on our comprehension of cancer at the molecular level. The breakthrough commenced in the mid-1970s, upon the discovery of oncogenes. During the 1980s, Dr. Fumimaro Takaku (1931-2022), the professor of the Third Department of Internal Medicine at the University of Tokyo, recognized the lack of molecular biology laboratories in clinical departments in Japan. Concerned that this deficiency would hinder the future provision of advanced therapies to patients, he established a laboratory (the Eighth Laboratory, Hachi-ken) to conduct research using molecular biological tools to developing new therapies for cancer. It must have been an arduous task for Prof. Takaku to establish a new laboratory with costly instruments and reagents in the 1980s when Japan was just starting to grow economically. Nevertheless, he surmounted the obstacle, and the laboratory has since produced numerous researchers who have each contributed to cancer biology. We are honored to hold this symposium in memory of Dr. Fumimaro Takaku, who passed away in 2022. We also deeply regret that Dr. Hisamaru Hirai, who strove to establish Hachi-ken as a leader and made significant contributions to leukemia research, cannot be among the speakers due to his premature death at the age of fifty-one.

変革する臨床試験

Live/On Demand9月23日（土）9:00～11:30　第4会場

座長：

大熊　ひとみ

国がん中央・国際開発部門

中村　能章

国立がん研究センター東病院

演者：

中村　能章

国立がん研究センター東病院

大熊　ひとみ

国がん中央・国際開発部門

谷口　浩也

愛知県がんセンター　薬物療法部

三角　俊裕

国がん東病院・データサイエンス部

新井　康之

京都大学医学部附属病院　細胞療法センター

企画趣旨・ねらい

様々な分析機能が開発される中、がん種の細分化が進むとともに、薬剤開発の複雑性が増してきた。そのような中、臨床試験の方法論にも変革が起こり、効率的に薬剤開発を進めようとする取り組みが行われつつある。最新の取り組みについてそれぞれの立場から紹介するとともに、トランスレーショナルリサーチから臨床データの利活用まで最適ながん創薬開発のあり方についてディスカッションを行う。

3学会合同シンポジウム（日本癌学会＋日本癌治療学会＋日本臨床腫瘍学会）
リキッドバイオプシーがもたらすがん医療の新世界

Live/On Demand9月23日（土）13:30～16:00　第16会場

座長：

高阪　真路

国立がん研究センター・研究所・細胞情報学

吉野　孝之

国立がん研セ・東病院

沖　英次

九州大学大学院　消化器・総合外科

演者：

高阪　真路

国立がん研究センター・研究所・細胞情報学

新井田　厚司

東大　医科研

Steven Olsen

Dept of Medical and Clinical Affairs, Guardant Health AMEA

沖　英次

九州大学大学院　消化器・総合外科

Jeanne Tie

Peter MacCallum Cancer Centre／Walter and Eliza Hall Institute of Medical Research／University of Melbourne

坂東　英明

国立がん研究センター東病院

企画趣旨・ねらい

Liquid biopsy (LB) is a method to acquire clinical information by detecting cfDNA, ctDNA, miRNA, exosomes, etc. in blood or urine. In unresectable advanced cancer, LB has already been clinically applied and reported to provide real-time information that cannot be obtained from the primary tumor tissue, enabling rapid drug selection. In addition to this, clinical development in the fields of cancer screening diagnosis (e.g., MCED) and recurrence diagnosis (MRD) is currently in progress, and future technological innovation has the potential to even make it possible to diagnose all aspects of cancer. We would like to discuss the status of these developments and future prospects from the basic to the clinical level.

2学会合同シンポジウム（日本癌学会＋日本腫瘍循環器学会）
腫瘍循環器学　―新たな学際領域の課題と今後の取り組み―

Live/On Demand9月23日（土）13:30～16:00　第17会場

座長：

石岡　千加史

東北大院・医・臨床腫瘍

小室　一成

国際医療福祉大学

演者：

小室　一成

国際医療福祉大学

石岡　千加史

東北大院・医・臨床腫瘍

田尻　和子

国立がん研究センター東病院・循環器科／筑波大学グローバル教育院

向井　幹夫

大阪国際がんセンター　成人病ドック科

佐瀬　一洋

順天堂大学大学院医学研究科・臨床薬理学

諫田　泰成

国立衛研・薬理

企画趣旨・ねらい

Onco-Cardiology is a novel interdisciplinary field aimed at addressing the emerging cardiovascular pathologies resulting from cancer treatment advancements and enhancing cancer treatment outcomes. Cardiotoxicity resulting from anthracyclines and radiotherapy has been known as cancer therapy-related cardiac dysfunction (CTRCD). However, new pathologies such as heart failure, coronary artery disease, hypertension, arrhythmia, thromboembolism, pericardial disease, and peripheral vascular disease have emerged due to molecularly targeted drugs and immune checkpoint inhibitors. Therefore, urgent research is needed to address these new cancer therapy-related cardiovascular toxicities (CTR-CVT) in terms of prevention, diagnosis, and treatment. Recently, the development of interdisciplinary practice guidelines has highlighted the unmet medical needs and evidence gaps in this field, driving the need for increased collaboration between the oncology and cardiology to support translational research. At this joint symposium of the Japanese Onco-Cardiology Society (JOCS) and the Japanese Cancer Association (JCA), we will discuss the current status and future challenges of Onco-Cardiology, exploring the opportunities for basic, clinical, and epidemiological research.

がん治療における老化細胞とSASP制御の新潮流

Live/On Demand9月21日（木）13:40～16:10　第3会場

座長：

高橋　暁子

（公財）がん研究会・がん研究所・細胞老化／NEXT・がん細胞社会成因解明PJ

Elaine Sanij

St Vincents Institute of Medical Research, Fitzroy, VIC, Australia／Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia／Department of Biochemistry and Molecular Biology, Monash University, VIC, Australia

演者：

高橋　暁子

（公財）がん研究会・がん研究所・細胞老化／NEXT・がん細胞社会成因解明PJ

Tae J. Park

Department of Biochemistry, Ajou University School of Medicine／Inflamm-Aging Translational Research Center, Ajou University Medical Center

Pinglong Xu

Life Science Institute, Zhejiang University

松本　知訓

大阪大学　微生物病研究所　遺伝子生物学

Elaine Sanij

St Vincents Institute of Medical Research, Fitzroy, VIC, Australia／Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia／Department of Biochemistry and Molecular Biology, Monash University, VIC, Australia

張　園園

金沢大学・がん進展制御研究所

企画趣旨・ねらい

In recent years, it has been reported that chemotherapy drugs such as CDK4/6 inhibitors and radiotherapy induce cellular senescence in cancer and stromal cells, which contributes to cancer treatment resistance and recurrence. Furthermore, senescent cells are involved in the development and malignancy of various cancers via senescence-associated secretory phenotype (SASP). Therefore, understanding the roles of senescent cells and SASP in the cancer microenvironment is expected to lead to control of the increase in cancer incidence with aging and the malignancy of cancer. Development of senolytic drugs targeting senescent cells and senomorphic drugs regulating SASP derived from senescent cells is actively underway for cancer prevention and treatment. In this session, we will discuss novel cancer treatment strategies targeting senescent cells and SASP in the cancer microenvironment.

がんの可塑性と適応性を動的に制御し組織多様性を生み出す遺伝子調節機構

Live/On Demand9月21日（木）13:40～16:10　第5会場

座長：

近藤　豊

名古屋大・院医・腫瘍生物

Shyam Prabhakar

Spatial and Single Cell Systems, A*STAR Genome Institute of Singapore

演者：

近藤　豊

名古屋大・院医・腫瘍生物

Hsuehping C. Chu

Institute of Molecular and Cellular Biology, National Taiwan University,Taiwan

井上　大地

神戸先端研・血液腫瘍研究部

Alfred Cheng

School of Biomedical Sciences, The Chinese University of Hong Kong

Tanapat Palaga

Department of Microbiology, Faculty of Science, Chulalongkorn University／Center of Excellence in Immunology and Immune Mediated Diseases, Chulalongkorn／Graduate Program in Biotechnology, Faculty of Science, Chulalongkorn University／Department of Microbiology, Faculty of Medicine, Chulalongkorn University

菊池　章

阪大・感染症拠点

Shyam Prabhakar

Spatial and Single Cell Systems, A*STAR Genome Institute of Singapore

企画趣旨・ねらい

Recent studies showed that gene expression is regulated by multiple layers of a dynamic coordination of regulatory factors at certain genomic loci. In many types of cancers, genetic alterations are found in such factors, especially epigenetic regulators, RNA splicing factors, and RNA binding proteins, indicating the crucial properties of these factors during carcinogenesis. Epigenetic regulators and other associated proteins in many important nuclear processes was shown to engage in multilayer cooperative interactions that dynamically regulate not only cancer cells but also the cells composing tumor microenvironment including different types of immune cells. These findings may raise a possibility of novel drug targets for cancer treatment. In this session, researchers from Asian counties discuss an emerging perspective of gene regulatory network, which contributes to establish tumor cells and their microenvironmental heterogeneity.

全ゲノム解析と新技術エピゲノム解析による包括的ながんゲノムの解明

Live/On Demand9月21日（木）13:40～16:10　第8会場

座長：

柴田　龍弘

東京大学・医科研・ゲノム医科学分野／国立がん研セ・研究所・がんゲノミクス

Bin T. Teh

National Cancer Centre Singapore, Singapore／Duke-NUS Medical School, Singapore

演者：

柴田　龍弘

東京大学・医科研・ゲノム医科学分野／国立がん研セ・研究所・がんゲノミクス

Raghav Sundar

National University Cancer Institute, Singapore

永江　玄太

東京大・先端研・ゲノムサイエンス

浅田　健

理研・AIPセ・がん探索医療研究チーム／国立がん研セ・研・医療AI研究開発分野

Bin T. Teh

National Cancer Centre Singapore, Singapore／Duke-NUS Medical School, Singapore

Jing Tan

Sun Yat-sen University Cancer Center

企画趣旨・ねらい

The Whole Cancer Genome Sequencing Project initiated in Japan has led to the accumulation of large-scale whole-genome data. However, to elucidate mutations and structural abnormalities in non-coding regions, which are expected to be newly discovered by whole-genome analysis, it is essential to understand functional genomic regions such as enhancers, transcriptional regulators, and long non-coding RNAs. Methods such as ChIP-seq and ATACseq, which assess chromatin status, have been incorporated into clinical samples, and the epigenomic status of the entire cancer genome is being clarified through allele-specific methylation analysis by long-read analysis and full-length transcriptome sequencing. In this session, we will focus on new research areas that integrate epigenomic and whole-genome analysis technologies, which are currently advancing rapidly, and invite international researchers, including young scientists, to present their latest research results and discuss the prospects for new cancer genome research starting from whole-genome data.

分子的側面から見たがん疫学の進歩

Live/On Demand9月22日（金）9:00～11:30　第2会場

座長：

岩崎　基

国立がん研セ・がん対策・研

Sue K. Park

Department of Preventive Medicine, Seoul National University College of Medicine

演者：

Sue K. Park

Department of Preventive Medicine, Seoul National University College of Medicine

小栁　友理子

愛知県がんセンターがん予防研究分野

Weangkee Ho

School of Mathematical Sciences, University of Nottingham Malaysia／Cancer Research Malaysia

山地　太樹

国立がん研究セ・がん対策セ・疫学研究部

Juesheng Ong

Dept. of Pop. Health., QIMRB, Australia

企画趣旨・ねらい

It has been a long time since “molecular epidemiology” was introduced into the field of cancer epidemiology. Initially, hypothesis-based research using functional single nucleotide polymorphisms (SNPs) was mainly conducted but various approaches using a SNP-chip along with advance in genotyping technic have emerged such as whole-genome association analysis, mendelian randomization analysis, and development of polygenic risk score. Although primary aim of epidemiology is to prevent cancer, application to preventive measures has been challenge due to limited evidence considering environmental factors in many large-scale studies. Against this background, the aim of this session is to present the latest approaches in molecular epidemiology of cancer by researchers representing the Asian region, and to promote future collaboration in molecular epidemiology of cancer in Asia.

がんのゲノム不安定性の新たな展望

Live/On Demand9月22日（金）13:40～16:10　第5会場

座長：

田中　耕三

東北大・加齢研

Pascal Duijf

University of South Australia & SA Pathology, Adelaide SA, Australia

演者：

Pascal Duijf

University of South Australia & SA Pathology, Adelaide SA, Australia

清光　智美

沖縄科学技術大学院大学・細胞分裂動態

高橋　元子

（公財）がん研・研・実験病理部

Kundan D. Sengupta

Biology, Indian Institute of Science Education and Research, Pune, INDIA

Fangwei Wang

Life Sciences Institute

家村　顕自

東北大加齢研分子腫瘍

企画趣旨・ねらい

Large-scale genomic analyses of cancer have shown that genomic instability is closely linked to cancer initiation, progression and drug resistance. It is also becoming clear how genomic instability arises at the cellular level and how it affects the properties of cancer cells. Furthermore, there is a growing trend to view genomic instability as a weakness of cancer cells and as a new therapeutic target. This International Session will discuss the latest findings on genomic instability in cancer at the cellular level, which complement large-scale genomic analyses of cancer and may lead to new therapeutic opportunities.

種々のがんモデル動物を用いた新しい診断法・治療法開発への挑戦

Live/On Demand9月22日（金）13:40～16:10　第8会場

座長：

細野　祥之

岡山大・院医歯薬・薬理学分野

Bushra Ateeq

Department of Biological Sciences & Bioengineering, Indian Institute of Technology Kanpur

演者：

三浦　恭子

熊本大 大学院生命

Wangta Liu

Department of Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan

園下　将大

北大・遺制研・がん制御学

Anjali Bajpai

Department Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur

田口　歩

愛知県がんセンター　分子診断TR分野／名古屋大・院医・先端がん診断学

杜　婉瑩

東京大学消化管外科

Bushra Ateeq

Department of Biological Sciences & Bioengineering, Indian Institute of Technology Kanpur

企画趣旨・ねらい

Advances in cancer research and in vivo model engineering are intricately linked and have grown hand in hand. The contribution of current models in the discovery of the new diagnostics and therapeutics is noteworthy. However, there exist large discrepancies between the actual clinical pathology and existing animal models, and new models that address these differences will further advance this field. Recent novel technological development enables researchers and clinicians not only to engineer new animal models, but also to re-purpose/re-engineer existing animal models such as zebrafish or fruit flies that have been utilized for a longtime. Due to limitations of existing animal models and increasing ethical regulations, the usage of these lower organism models will play important roles in both understanding of pathophysiological elucidation and developing new diagnostic and therapeutic strategies. In this session, we aim to discuss various emerging animal models that is likely to have a profound impact in the years to come.

がんのライフサイクルにおけるゲノム/エピゲノム適応

Live/On Demand9月22日（金）13:40～16:10　第15会場

座長：

金田　篤志

千葉大・医・分子腫瘍学

Patrick Tan

Duke-NUS Medical School／Genome Institute of Singapore／Cancer Science Institute of Singapore, NUS

演者：

金田　篤志

千葉大・医・分子腫瘍学

Patrick Tan

Duke-NUS Medical School／Genome Institute of Singapore／Cancer Science Institute of Singapore, NUS

Angela R. Wu

Division of Life Science, HKUST／Department of Chemical and Biological Engineering, HKUST／HKB Guangdong Southern Marine Science and Engineering Laboratory (Guangzhou), HKUST／Center for Aging Science, HKUST

越智　陽太郎

京都大学　腫瘍生物学／ヒト生物学高等研究拠点(ASHBi)

Qiang Y. Yu

Genome Institute of Singapore

竹内　千尋

星薬科大学エピゲノム創薬研究室／国立がん研セ・研・エピゲノム／東京大・医附属病院・消化器内科

益田　宗幸

国立病院機構九州ガンセンター　頭頸科

企画趣旨・ねらい

As represented by cancer genome therapy, comprehensive omics analysis and its medical application have been remarkably conducted and tried in cancer field. Many issues are, however, yet to be solved such as development of accurate cancer risk prediction and prevention, detailed stratification of treatment and recurrence prediction, and novel therapeutic agents for recurrent and refractory tumors. While cells are exposed to various carcinogenic factors and microenvironments, they adapt and evolve their genome structures and epigenome modifications in various ways from precancerous stages accumulating cancer risks to development of cancer, during progression and metastasis, or acquiring resistance to treatment during recurrence. Through various analytic approaches such as three-dimensional chromatin structure, spatial transcriptome, and single-cell analysis, elucidation of such genome/epigenome adaptation of cancer cells in their lifetime and development of medical strategies are comprehensively conducted in Japan and Asia. We will discuss on frontier studies in this field and disseminate cutting-edge information in this session.

がん微小環境を標的としたがん治療開発の新展開

Live/On Demand9月22日（金）13:40～16:10　第16会場

座長：

渡部　徹郎

東京医歯大・医歯総合・病態生化学

Pilhan Kim

Grad. Sch. of Med. Sci. Eng., KAIST

演者：

Pilhan Kim

Grad. Sch. of Med. Sci. Eng., KAIST

間石　奈湖

北大・院歯・血管生物分子病理

Keehoon Jung

Seoul National University College of Medicine

田中　美和

がん研・がんエピゲノム

内藤　尚道

金沢大学医薬保健研究域・血管分子生理学

Jihwan Park

West China Hospital, Sichuan University

渡部　徹郎

東医歯大・医歯総合・病態生化学

企画趣旨・ねらい

Dynamic interactions of cancer cells with their microenvironment consisting of stromal cells and extracellular matrix components play important roles in the evolution of cancer cells. Components of tumor stroma, including tumor vessels, cancer associate fibroblasts and immune cells, are also affected by cancer cells and communicate with them. Increasing lines of evidence have suggested that these mutual interaction between cancer cells and tumor stroma alter the tumor microenvironment, which leads to cancer progression and metastasis. Therefore, understanding the underlying cellular and molecular mechanisms governing these interactions can be used as a novel strategy to disrupt cancer cell interplay and contribute to the development of efficient therapeutic strategies to fight cancer. In this symposium, leading scientists in the field of tumor microenvironment will introduce the recent progress in their fields, and discuss how to develop effective and safe cancer therapies by targeting the tumor microenvironment.

変容する世界におけるがん対策ー2023世界がんリーダーズサミットへのアジアからの提言

Live/On Demand9月23日（土）9:00～11:30　第8会場

座長：

野田　哲生

（公財）がん研・研

演者：

Jeff Dunn

President, UICC

Saunthari Somasundaram

President, National Cancer Society Malaysia

Mark Britnel

Professor, University College London

西嶋　康浩

厚生労働省 がん・疾病対策課長

小口　正彦

がん研究会 がん研有明病院 顧問/医療情報部　部長

坂野　哲平

株式会社アルム 代表取締役社長

Murallitharan Munisamy

Director, National Cancer Society Malaysia

放射線治療や放射線生物学の新しい潮流

Live/On Demand9月23日（土）9:00～11:30　第15会場

座長：

長谷川　純崇

量子科学技術研究開発機構

Ikjae Lee

Dept. of Radiation Oncology, Yonsei University College of Medicine

演者：

Ikjae Lee

Dept. of Radiation Oncology, Yonsei University College of Medicine

李　惠子

量研機構・重粒子・がん生物

飯島　茂異人

UTSW・放射線腫瘍学研究室／慶應義塾大学医学部産婦人科学教室

Michael L. Wang

Division of Radiation Oncology, National Cancer Centre Singapore

Yiwei Chen

Department of Radiation Oncology, Taipei Veterans General Hospital

渡部　直史

阪大医核

企画趣旨・ねらい

The focus of this session is to create a forum on new trends in radiation therapy and radiobiology in cancer researcher’s community. Radiation therapy has been established as a standard therapy against cancer and widely applied to treatment for various cancers. Recently, new radiation therapies have emerged; proton beam therapy, heavy ion therapy, boron neutron capture therapy, targeted alpha therapy and so on. These radiotherapeutic modalities impact on oncology not only in Europe and the United States, but also in Asia and Oceania. In order to accelerate these trends and further develop next generation radiation therapy, the contribution of radiobiology is fully expected. Radiobiology has so far made a great contribution not only to radiation oncology but also life sciences including cancer research. However, there are many challenging issues to be addressed, especially the biological or biophysical effects on living body after irradiation. New findings and technical advances in radiobiology will lead to the innovation of radiation therapy. In this session, we will invite cutting-edge researchers and radiation oncologists in Asia and Oceania to share our future on radiation therapy and radiobiology.

生物進化の観点から捉え直す多段階発がん

Live/On Demand9月23日（土）9:00～11:30　第16会場

座長：

筆宝　義隆

千葉県がんセ・研

Tao Liu

Children's Cancer Institute Australia, The University of New South Wales

演者：

Jason W. Wong

School of Biomedical Sciences, University of Hong Kong

加藤　護

国がんセ・研究所・バイオインフォ

末永　雄介

千葉がんセ 研 進化腫瘍学

Tao Liu

Children's Cancer Institute Australia, The University of New South Wales

長畑　洋佑

京大医生研・再生免疫学分野／京大大学院・医・血液腫瘍内科学

Javier Koh

Cancer and Stem Cell Biology, Duke-NUS Medical School

企画趣旨・ねらい

On one hand, multistep carcinogenesis bears a high degree of similarity to Darwin's definition of evolution because it is characterized by heterogeneous cells with the ability to self-renew and by selection pressure from the microenvironment. On the other hand, it clearly differs from biological evolution in that cancer evolution is initiated by a genome that is already complex from the start, and epigenetic effects promote cancer evolution. Indeed, some tumors develop with minimal genetic changes, while cellular plasticity contributes to both tumor development and progression. However, an evolutionary theory capable of explaining these features of the carcinogenic process has not yet been established. Therefore, in this session, we call for theoretical and experimental studies to understand cancer evolution and to enable evolutionary-based cancer diagnosis and treatment strategies. Specifically, this includes single-cell analysis of cancer tissue, spontaneous carcinogenesis from non-human species, and studies focusing on the contribution of cell lineage-specific genes to carcinogenesis. In addition, proposals for new theories specific to cancer evolution and research on therapeutic strategies based on cancer evolutionary theory are also welcome.

プロテオゲノミクス解析が切り拓く新たながん治療･診断戦略

Live/On Demand9月23日（土）13:30～16:00　第5会場

座長：

植田　幸嗣

（公財）がん研

Sangwon Lee

Center for Proteogenome Research, Department of Chemistry, Korea University

演者：

Henry Rodriguez

Office of Cancer Clinical Proteomics Research, NCI

植田　幸嗣

がん研・CPMセ・プロテオミクス解析Gr

Qiang Gao

Department of Liver Surgery and Transplantation, Zhongshan Hospital

西塚　哲

岩手医大・医歯薬総合・医療開発

Sangwon Lee

Center for Proteogenome Research, Department of Chemistry, Korea University

阿部　雄一

愛知県がん研究所・分子診断TR分野

企画趣旨・ねらい

With the development of various omics analysis technologies in recent years, multi-omics analysis research is being actively conducted around the world, which can further develop the results of mature cancer genomics research.
In particular, in the field of proteogenomics analysis research that integrates genomics and proteomics, The International Cancer Proteogenome Consortium (ICPC), in which 14 countries participate, was established in 2016 under the leadership of the Cancer Moonshot Project in the United States.
In this framework, many important findings have been reported, including new cancer stratification and discovery of therapeutic targets based on proteogenomics. Moreover, further important discoveries are expected to be made in this field, from basic cancer biology to findings that will lead to clinical applications under global research collaborations and AI-assisted big data infrastructure.
In this session, we would like to provide an opportunity to learn about the new possibilities offered by proteogenomics analysis by inviting researchers with distinguished achievements and leadership in Asian countries.

AIが切り拓くがん研究の新時代

Live/On Demand9月21日（木）9:00～11:30　第2会場

座長：

浜本　隆二

国立がん研究セ・研・医療AI研究開発／理研・革新知能統合研究セ・がん探索医療

石川　俊平

東京大学　大学院医学系研究科　衛生学教室／国立がん研究センター　EPOC　臨床腫瘍病理

演者：

浜本　隆二

国立がん研究セ・研・医療AI研究開発／理研・革新知能統合研究セ・がん探索医療

石川　俊平

東京大学　大学院医学系研究科　衛生学教室／国立がん研究センター　EPOC　臨床腫瘍病理

竹下　修由

国がん東・医療機器開発推進部門

清水　秀幸

医科歯科大・データ科学・AIシステム医科学

Yen H. Chen

Institute of Biomedical Sciences, Academia Sinica

企画趣旨・ねらい

Expectations for artificial intelligence (AI) are rising with rapid advances in machine learning technology, particularly deep learning. AI is currently being introduced in various areas of society, and the medical field is no exception, with AI-based medical devices already in use not only at the research level but also in clinical practice. In cancer research, AI is beginning to be actively utilized in a wide range of fields, including analysis of medical images such as endoscopic images, pathological images, and radiological images, omics analysis, and drug discovery. In particular, recent cancer research requires analysis of large-scale data such as whole genome data and multimodal analysis of data from various modalities, and AI-based cancer research is expected to become increasingly important in the future. Therefore, this symposium will be held to present the latest results of AI-based cancer research and to help participants understand the current status of AI-based cancer research.

がん生殖細胞系列ゲノミクス解析の新潮流

Live/On Demand9月21日（木）9:00～11:30　第4会場

座長：

岡田　随象

東京大・院医

鎌谷　洋一郎

東京大・院新領域創成

演者：

谷川　千津

東京大学大学院・新領域創成科学研究科

曽根原　究人

東京大学・医・遺伝情報学／大阪大学・医・遺伝統計学／理化学研究所・IMS・システム遺伝学

河野　隆志

国立がんセ・C-CAT／国立がんセ研・ゲノム生物

斎藤　優樹

国立がん研究セ・研・分子腫瘍／慶應大・医・消化器内科

赤木　究

埼玉県立がんセンター　腫瘍診断・予防科

企画趣旨・ねらい

Both somatic and germline mutations play essential roles in cancer genomics. While our knowledge on somatic mutation spectra in cancers have developed in the last decade, we still do not know well how germline mutations affect carcinogenesis. To date, biological and clinical interaction between somatic and germline mutations is still elusive. Recent development of high throughput sequencing technology and the national biobank resources have elucidated that rare, low frequency, common, and genome-wide polygenic germline mutations synergically affect susceptibility and/or prognosis of a wide range of human cancers. Bioinformatics and machine learning methodologies to integrate such germline mutations and multi-layer human omics information becomes important. Contribution of the environmental factors, namely gene environmental interaction, is another important modality to understand cancer germline mutation pathogenesis. In this session, we have a series of the invited talks and panel discussions focusing on the latest updates of the cancer germline mutations towards personalized medicine.

ゲノム情報解析の最先端: ヒトゲノムのダークマター領域の謎に迫る

Live/On Demand9月21日（木）9:00～11:30　第5会場

座長：

森下　真一

東京大

白石　友一

国立がん研究センター・研究所

演者：

Erik Garrison

Department of Genetics, Genomics, and Informatics, UTHSC

小林　武彦

東京大学定量生命科学研究所（東大定量研）

深川　竜郎

大阪大学・生命機能

鈴木　裕太

東大・新領域・メディカル情報生命

白石　友一

国立がん研究センター・研究所

企画趣旨・ねらい

近年のロングリードシークエンス技術の進歩により、特殊な繰り返しの塩基配列で構成されているセントロメア領域、リボソームRNA遺伝子領域等の詳細な分析が可能となりつつある。本セッションにおいては、ゲノム上の難読領域に関連する研究に取り組む情報系・実験系の研究者からの講演を通じて、ゲノム解析研究の現在地を把握しつつ、今後の方向性について洞察を深めることを目標とする。

エピゲノムの今未来

Live/On Demand9月21日（木）9:00～11:30　第8会場

座長：

岩間　厚志

東京大学・医科学研究所・幹細胞分子医学

村川　泰裕

京大・ヒト生物学高等研究拠点／理研・生命医科学研究センター／IFOM癌研究所

演者：

早野　元詞

慶應義塾大学医学部整形外科学教室

村川　泰裕

京大・ヒト生物学高等研究拠点／理研・生命医科学研究センター／IFOM癌研究所

Rong Fan

Dept. of Biomedical Engineering

山岸　誠

東京大学・院・新領域・メディカル情報生命

岩間　厚志

東京大学・医科学研究所・幹細胞分子医学

Ricky W. Johnstone

Peter MacCallum Cancer Centre

企画趣旨・ねらい

Recent advances in molecular biology and functional genomics have enabled the identification of epigenetic alterations in specific genes and pathways that contribute to tumorigenesis. In addition, the use of epigenetic therapies, such as DNA methylation inhibitors and histone deacetylase inhibitors, has shown promise in the treatment of certain types of cancer. However, many challenges still remain in the field of cancer epigenetics to fully understand the mechanisms of cancer development and maintenance. In this symposium, we will discuss the recent efforts to fully understand the complex interplay between genetics and epigenetics in tumorigenesis. We will also talk about emerging concepts of epigenetics related to the aging process, a major risk factor for various cancers. Furthermore, we will introduce an array of new and disruptive technologies to reveal new aspects of cancer epigenomics. These technologies include functional genomics tools that allow detailed studies of cancer epigenomics at high genomic resolution, as well as spatial epigenomic profiling methods at the single-cell level. This symposium aims to provide a forum for a lively discussion of new biology and technologies that will open up new directions in cancer epigenetics research.

複雑な転移機構に迫る新しいがん生物学

Live/On Demand9月21日（木）9:00～11:30　第16会場

座長：

大島　正伸

金沢大

榎本　篤

名古屋大・院医・腫瘍病理学

演者：

Hugo J G Snippert

UMC Utrecht & Oncode Institute

星野　歩子

東京大学・先端科学技術研究センター

平田　英周

金沢大・がん研・腫瘍細胞生物学

Yoshiaki Ito

Cancer Science Institute of Singapore, National University of Singapore

青木　正博

愛知がんセ・研・がん病態生理／名古屋大・医・がん病態生理

Sauyee Kok

Div. Genetics, Cancer Res. Inst, Kanazawa Univ

企画趣旨・ねらい

Most of cancer-related death is caused by metastasis, thus it is important to understand the molecular mechanism of metastasis to develop novel therapeutic strategy. Recent genome analysis demonstrated that accumulation of driver mutations is confirmed in the primary cancer tissues, and the metastasis-specific genetic alterations are rarely found. On the other hand, there have been shown to be novel biological mechanisms that include extracellular vesicle-led premetastatic niche generation, education of tumor-promoting stromal cells for survival of disseminated tumor cells, cell cluster migration and polyclonal metastasis, and stemness-regulated dormancy of the drug-resistant cells, etc. In this symposium, we would like to discuss about such novel biological mechanisms to expand our knowledge about metastasis development.

最先端プロテオーム解析技術が導く新たながん研究

Live/On Demand9月21日（木）13:40～16:10　第14会場

座長：

芳賀　淑美

（公財）がん研

足達　俊吾

国立がん研セ

演者：

峯岸　ゆり子

がん研・CPMセ・プロテオミクス解析Gr

田口　歩

愛知がん・分子診断TR／名古屋大・医・先端がん診断

小田　吉哉

東京大学大学院医学系研究科

足立　淳

医薬健栄研・創薬標的プロテオミクスPJ

川島　祐介

かずさＤＮＡ研

伊吉　祥平

名古屋大学大学院医学系研究科産婦人科／フライブルク大学附属病院外科系病理部／名古屋大学高等研究院

企画趣旨・ねらい

Understanding cancer and developing treatments requires analyses not only genetic mutations but also the quantity and activity of proteins that regulate functions. With the advances of technologies such as next-generation DNA sequencing and RNA sequencing, genomic analysis in cancer has contributed to the identification of driver mutations and the development of targeted therapies. Although proteomics has lagged somewhat behind genomics, recent advances in proteomics technology over the past years have enabled direct, in depth, and quantitative analysis of the abundances of various cancer-related proteins, as well as their cancer specific amino acid alterations and post-transrational modifications in clinical samples. Deep proteomic profiling provides clinically useful information in various aspects, such as understanding the mechanisms of cancer physiology, and also discovering targets for diagnosis and anti-cancer agents. In this symposium, the cutting-edge proteomics technologies will be presented to provide an understanding of the current status of the latest clinical proteomics. Various topics will be covered, including the challenge of single-cell proteomics and integration with genomics. We hope to increase understanding of the potential and utility of different types of state-of-the-art proteomics platforms, and to promote collaborative research and clinical applications in the future.

がん疫学研究をサイエンスにするためのあたらな研究の取り組み

Live/On Demand9月21日（木）13:40～16:10　第15会場

座長：

松尾　恵太郎

愛知がんセ・研・がん予防

井上　真奈美

国立がん研セ・がん対策・研

演者：

野村　周平

慶應義塾大学 医療政策・管理学教室／東京大学大学院 国際保健政策学教室／東京財団政策研究所

伊藤　秀美

愛知県がんセ・がん情報・対策研究分野

碓井　喜明

理化学研究所基盤技術開発研究チーム

松尾　恵太郎

愛知がんセ・研・がん予防

井上　浩輔

京都大学・白眉センター／京都大学大学院医学研究科　社会疫学

澤田　典絵

国がん・がん対策研・コホート研究部

企画趣旨・ねらい

近年、疫学研究領域では、様々な情報利用が可能となり、その研究手法も多角化してきている。がん疫学においてメカニズムの解明に迫る研究を展開していくには、従来の研究展開に留まらず、新たな視点による解析手法の積極的導入を進めていくことが重要である。本シンポジウムでは、がん疫学研究の新展開に貢献できる可能性のある新たな研究手法やその取り組みについて、様々な視点からお話しいただく。

進化する遺伝子スクリーニング技術

Live/On Demand9月21日（木）13:40～16:10　第16会場

座長：

園下　将大

北海道大・遺伝研

武田　はるな

国立がん研セ・研究所

演者：

武田　はるな

国立がん研セ・研究所

前田　高宏

九州大学医学研究院プレシジョン医療学

占部　文彦

慈恵医大・医・泌尿器科／国立がん研セ・研・病態情報

小玉　尚宏

大阪大・消化器内科

青木　一成

京都大学医生物学研究所幹細胞遺伝学

井垣　達吏

京大・生命・システム機能学

企画趣旨・ねらい

Recent studies have made remarkable strides in elucidating the pathogenesis of cancer. Specifically, determining the key signaling pathways involved in carcinogenesis has been pivotal in understanding the mechanisms underlying cancer development and progression. Moreover, the identification of novel therapeutic targets has significantly promoted the development of anti-cancer drugs. In these studies, various screening technologies have contributed to delineating previously unappreciated genes governing cancers. For example, genome-wide genetic approaches in organoids and whole animals have unveiled essential genes implicated in cancer development, progression, and therapy resistance. This symposium invites six speakers who will present their cutting-edge achievements in various domains, including cancer initiation and progression. Sharing and discussing the latest methodologies and findings should open up new avenues for accelerating cancer research.

包括的緩和医療のための神経ネットワークによるがん病態に対する円環的修飾の解析

Live/On Demand9月21日（木）13:40～16:10　第17会場

座長：

成田　年

星薬大・薬理／国立がん研究セ・研・がん患者病態生理

天谷　文昌

京都府立医科大学　疼痛・緩和医療学教室

演者：

天谷　文昌

京都府立医科大学　疼痛・緩和医療学教室

今井　哲司

和歌山県立医科大学・薬学部・医療開発薬学

高橋　秀聡

横浜市立大学・耳鼻咽喉科・頭頸部外科

成田　年

星薬大・薬理／国立がん研究セ・研・がん患者病態生理

企画趣旨・ねらい

The cancer immune response is not determined solely by the number and nature of cancer cells themselves, but rather is tightly regulated by the tumor microenvironment based on the association between cancer cells and heterologous cells, as well as by circulating endotoxins, cytokines, hormones, exosomes, immune cell responses, and even brain-peripheral nerve linkages. The "negative cancer-immune chain" is thought to involve a circular network of brain-based afferent and efferent nerves, which is significant for elucidating their structure and function. A growing body of clinical evidence suggests that residual pain significantly worsens the prognosis of various diseases including cancer. Thus, excessive pain signals can alter immune cell responses through systemic neural networks including sensory neurons, and weaken the organism. The importance of "mental care" in the treatment of pain is evident because patients with cancer pain often exhibit psychiatric issues. Therefore, we propose that an integrated understanding of the "comprehensive cancer pathophysiology" that includes bio-sensory and systemic neural networks, including dispersive local interactions between heterologous cells in the cancer microenvironment, is required. In this symposium, we focus on the effects of changes in peripheral-brain neural networks on cancer pathophysiology.

がんのRNA異常の核心に迫る

Live/On Demand9月22日（金）9:00～11:30　第3会場

座長：

井上　大地

神戸医療産業都市推進機構先端医療研究セ

鈴木　洋

名古屋大

演者：

Michael G. Kharas

Molec. Pharm. Program, MSKCC

Eric Wang

The Jackson Laboratory

依田　成玄

京都大学　医学研究科　腫瘍生物

鈴木　美穂

名古屋大・医・腫瘍生物学

西村　耕太郎

神戸先端医療研究センター血液・腫瘍研究部

企画趣旨・ねらい

Gene regulation is fundamental to cell activity and malignant transformation, in which a manifestation of changes in gene expression facilitate the growth and spread of cancer cells into foreign niches. Recent advances in cancer research have highlighted that alterations in multiple layers of RNA regulation, including transcription, RNA splicing, RNA editing and modification, RNA 3’-end processing, non-coding RNA regulation, and biomolecular condensate regulation, are widespread in cancer cells beyond genomic alterations, contributing to cancer hallmarks and cancer diversity, and further opening a new avenue for cancer treatment. As understanding of the basic mechanisms of RNA regulation has continued to grow in recent years, the spectrum of RNA dysregulation also interplays with genetic, epigenetic, and translational mechanisms to shape altered gene expression programs in cancer. In addition, technological advances in RNA biology, such as bioinformatics, next-generation sequencing, genome/RNA engineering, and single cell analysis, have elaborated system-level understanding of RNA dysregulation in cancer and identified novel targets for therapeutic development. This symposium will connect domestic and foreign researchers and discuss the cutting edge and future of RNA research in cancer biology.

多様ながんモデルが紐解くがんバイオロジー

Live/On Demand9月22日（金）9:00～11:30　第4会場

座長：

藤井　正幸

慶大・医・医化学

柳下　薫寛

国がん研究所・分子薬理研究分野

演者：

藤井　正幸

慶大・医・医化学

柳下　薫寛

国がん研究所・分子薬理研究分野

山田　泰広

東京大・院医・分子病理

波江野　洋

東京理科大学・生命医科学研究所

齊藤　頼子

理化学研究所

細野　祥之

岡山大学・学術研究院医歯薬学域・薬理学

網代　将彦

国立がん研究センター・がんRNA

企画趣旨・ねらい

Due to the inability to model cancer in a living human body, researchers have developed various cancer models to simulate and investigate aspects of cancer in the laboratory, including mechanisms of cancer development, progression and drug sensitivity. Such models now encompass a panoply of in vitro, in vivo and computational models, with each model having its own strength and weakness. Although these model systems have provided significant insights into cancer biology, each model is in part self-contained and perhaps being used in its own research culture and community, hampering translational and transinstitutional effort toward the same goal of understanding cancer for human well-being. The use of cancer models that involve human tissues requires an adjustment of ethical issues, which also should not be overlooked. In this symposium, we would like to share our exciting insights obtained from a variety of cutting-edge cancer models. Through active discussion, we aspire not only to deepen our fundamental understanding of cancer biology but also to facilitate collaborative research through mutual recognition of each model and expertise.

変革する免疫細胞創薬

Live/On Demand9月22日（金）9:00～11:30　第15会場

座長：

籠谷　勇紀

慶應義塾大学医学部・先端研がん免疫

渡邊　慶介

国立がん研究センター　腫瘍免疫研究分野

演者：

寺倉　精太郎

名古屋大学医学部附属病院・血液内科

永井　純正

京都大学医学部附属病院・医療開発部

横須賀　忠

東京医大・医・免疫

Greg Allen

Dept of Medicine, University of California San Francisco

籠谷　勇紀

慶應義塾大学医学部・先端研がん免疫

渡邊　慶介

国立がん研究センター　腫瘍免疫研究分野

企画趣旨・ねらい

Cancer immunotherapy has been established as an effective therapeutic option for various types of cancer. Especially, adoptive immunotherapy is emerging as a potentially curative approach as represented by recent success of chimeric antigen receptor (CAR)-engineered T cell therapy against hematologic malignancies. However, multiple challenges still exist for this therapy, including poor efficacy against solid tumors, the development of serious immune-related side effects, huge economic costs required for the preparation of individual infusion products. Intensive efforts are currently in progress to further improve efficacy, safety, and versatility of this therapy. Since cell therapy is a “living drug”, we can modify and craft cells and their derivatives in a synthetic biology approach. In this symposium, we will introduce recent topics on basic, translational, and clinical research in cell-based immunotherapy. We will also discuss potential issues to accelerate clinical development of cell products from the standpoint of regulatory science.

がん全ゲノムプロジェクトの現状とがん医療の未来

Live/On Demand9月22日（金）13:40～16:10　第2会場

座長：

井元　清哉

東京大学・医科研・HGC

上野　貴之

がん研有明病院・がんゲノム医療開発部／がん研有明病院・乳腺外科

演者：

市村　崇

厚生労働省医政局研究開発政策課

天野　慎介

一般社団法人全国がん患者団体連合会

横野　恵

早稲田大学・社会科学部

井元　清哉

東京大学・医科研・HGC

勝屋　友幾

国立がん研究センター中央病院　先端医療科

上野　貴之

がん研有明病院・がんゲノム医療開発部／がん研有明病院・乳腺外科

企画趣旨・ねらい

Cancer genomic medicine in Japan began in earnest with the implementation of gene panel testing covered by national health insurance in June 2019. However, the information obtained from this testing is limited to less than 0.1% of the entire genome. To enhance the effectiveness of therapy, understand the intricate biology of cancer, and develop new therapeutic drugs, it has become essential to promote the analysis of the whole genome, including the exploration and clarification of unknown regions. In December 2019, an action plan for whole genome analysis was formulated, and in April 2021, the project for the full-scale operation of cancer whole genome analysis was launched. With major technical and scientific advances in genome analysis, such as long-read analysis, the human full-length genome sequence was read in 2022, further boosting cancer whole genome analysis. Our symposium aims to discuss the current status of the cancer whole genome project and its future prospects for cancer medicine from a multifaceted perspective.

正常組織におけるクローン進化

Live/On Demand9月22日（金）13:40～16:10　第3会場

座長：

小川　誠司

京都大

吉田　健一

国立がん研究セ・研究所・がん進展研究分野／ウェルカムサンガー研究所

演者：

西村　友美

京都大・医・腫瘍生物学／京都大・医・次世代臨床ゲノム医療／京都大・医・乳腺外科

吉里　哲一

カロリンスカ研究所　HERM

George Vassiliou

Cambridge Stem Cell Institute, University of Cambridge／Department of Haematology, University of Cambridge

吉田　健一

国立がん研究セ・研究所・がん進展研究分野／ウェルカムサンガー研究所

Jean Soulier

Hopital Saint-Louis, Paris, France／University Paris Cite／INSERM

Youngseok Ju

Korea Advanced Institute of Science and Technology, Republic of Korea／Genome Insight Inc., San Diego, CA, USA

企画趣旨・ねらい

Almost all cancers are caused by somatic mutations, which accumulate in normal tissues by aging and exposures to environmental factors, such as smoking and alcohol drinking. Recent reports have revealed the early clonal expansion caused by cancer driver mutations in normal tissues of various organs and subsequent development of precancerous lesions. In addition, clonal evolution characterized by driver mutations, which follow a different pattern from that in cancers in corresponding tissues, were identified in healthy individuals and patients with inflammatory diseases, suggesting different roles of positively selected clones in normal aging and non-neoplastic diseases. Moreover, early acquisition of somatic mutations and clonal evolution have been shown in tissues of patients with some cancer predisposition syndromes.
In this symposium, six speakers will present their recent works on somatic mutations and clonal evolution in normal tissues and their relationships with cancer and other diseases, which would provide us the opportunity to better understand the early carcinogenesis.

新世代のイメージング技術

Live/On Demand9月22日（金）13:40～16:10　第4会場

座長：

浦野　泰照

東京大・院薬

鈴木　健一

岐阜大学　糖鎖生命コア研究所／国立がん研究センター研究所

演者：

鈴木　健一

岐阜大学　糖鎖生命コア研究所／国立がん研究センター研究所

永井　健治

大阪大学・産研／大阪大学・先導機構

福間　剛士

金沢大・ナノ生命科学研

柳下　淳

東京大学 カブリ数物連携宇宙研究機構

藤田　恭平

東大院・医／JST ACT-X

企画趣旨・ねらい

To elucidate the pathogenic mechanism of cancer, it is extremely important to precisely image intracellular signal transduction, molecular interactions, and intercellular networks, as well as their disruption during cellular oncogenesis. To realize precise visualization and diagnosis of cancer as a clinical technology, it is essential to develop multimodal imaging technology that enables visualization and analysis of multiple targets in a multicellular environment. In this symposium, we will introduce the development of various state-of-the-art imaging probes and devices ranging from single molecule and super-resolution observation in cells to multicellular imaging and in vivo cancer imaging in individuals. The latest research on cancer cell biology and the creation of clinical medical technologies using these probes and devices, as well as the future prospects will be showcased.

変わりゆく研究者のワークライフバランス ～共にウェルビーイングを目指して～

Live/On Demand9月22日（金）13:40～16:10　第17会場

座長：

山内　英子

Univ. of Hawaii Cancer Ctr.

大槻　雄士

藤田医科大・総合医科学研究部門

演者：

越前　佳奈恵

大阪公立大学・医・病態生理学

畔堂　一樹

産業技術総合研究所 阪大フォトバイオOIL／大阪大学　工学研究科

川堀　真人

北海道大学　医学部　脳神経外科

上野　直人

ハワイ大・がんセンター・乳がん部門

藤川　葵

厚生労働省医政局医事課

企画趣旨・ねらい

This special program will be held to illuminate the future of cancer research by promoting interaction among all participants, including speakers and audiences. From the 81th JCA meeting, this symposium was planned to be held with participation of scientists from a wide range of backgrounds. This year, we entitle this symposium as "Life-work balance for Scientists to the New Era ～Aiming for Well-being together～". The purposes of this program are (1) to share the know-how to maintain the healthy Life-work balance, (2) to discuss how to improve the Life-work balance as a SCIENTIST and (3) to create together the COMPASS by which scientists can reach “Well-being” life. To achieve these goals, we will invite scientists who have different backgrounds and are currently trying toward their own goals. We do believe that this symposium will be a precious opportunity to share new insights to brighten your own research life.

腫瘍微小環境の免疫学的特徴とがん免疫療法

Live/On Demand9月23日（土）9:00～11:30　第5会場

座長：

冨樫　庸介

岡山大学・医・腫瘍微小環境

小山　正平

国立がん研究センター／大阪大学大学院医学系研究科

演者：

冨樫　庸介

岡山大学・医・腫瘍微小環境

Cheng L. Yang

Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital

大脇　貴之

名古屋大学病院　泌尿器科

田中　伸之

慶應義塾大学　医学部　泌尿器科学教室

白　康晴

京大　がん免疫総合研究センター

小山　正平

国立がん研究センター／大阪大学大学院医学系研究科

Roberta Zappasodi

Weill Cornell Medicine, New York／Weill Cornell Graduate School of Medical Sciences, New York, NY

企画趣旨・ねらい

Cancer immunotherapies such as monoclonal antibodies against PD-1/PD-L1 or CTLA-4 have been approved in the treatment for various types of cancer, leading to a paradigm shift in cancer treatment. However, their efficacies are unsatisfactory as monotherapies. It is essential to understand the mechanisms of treatment sensitivity and resistance in the tumor microenvironment (TME) to increase efficacy. Various novel technologies including single-cell sequencing and imaging system have made it possible for us to elucidate the TME in detail. In addition, new insights into the tumor metabolic environment, the molecular mechanisms of immune checkpoints, and the balance between immunogenicity and oncogenic function of gene mutations have been uncovered. In this symposium, six presenters will show novel insights about the TME based on their latest findings.

染色体インテグリティとその破綻

Live/On Demand9月23日（土）9:00～11:30　第17会場

座長：

斉藤　典子

（公財）がん研・研

岡部　篤史

千葉大・院医・分子腫瘍

演者：

岡部　篤史

千葉大・院医・分子腫瘍

三浦　尚

理研・BDR

立和名　博昭

がん研・がん生物

富松　航佑

九大・生医研

武井　洋大

カリフォルニア工科大・生物

落合　博

九大・生医研・遺伝子発現動態

企画趣旨・ねらい

Genomic DNA in the nucleus is not randomly positioned, but constitutes chromosomes containing supra-molecular complexes of chromatin fibers and highly folded into three-dimensional (3D) structures. Higher-order chromatin structures include chromosome territories, active A- and inactive B- compartments, topologically associating domains (TADs), and chromatin loops. They are based on linear genome (nucleotide sequence itself) and epigenome (modification on genome) information, including DNA and histone modifications, and nuclear structures. 3D genome structures like A/B-compartments and the local interactions between promoter and regulatory elements vary depending on developmental or differentiation stages, and alter in response to environmental stresses and in diseases. Chromatin looping brings the gene and regulatory elements in close proximity for interactions, where gene expression is tightly regulated in each cellular state. Chromatin conformation capture techniques such as Hi-C, multiplexed super-resolution microscopy with sequential FISH and sequential immunofluorescence, live-cell imaging, and intensive computational analyses have contributed understanding of integrated spatial genomics and multi-omics in diverse biological phenomena. In this symposium, frontier studies driven by cutting-edge technologies will be presented by outstanding young researchers. We will discuss on the integrity of chromosome and chromatin structure in cells and its disruption leading to cancer development and progression.

共生細菌とがん免疫応答

Live/On Demand9月23日（土）13:30～16:00　第3会場

座長：

大谷　直子

大阪公立大・院医

早河　翼

東京大・医・消化器内科

演者：

山岸　良多

大阪公立大・院医・病態生理学

津軽　開

慶應義塾大学医学部　消化器内科

山田　裕貴

ミヤリサン製薬株式会社　研究開発本部

Daniel L. Worthley

Colonoscopy Clinic

早河　翼

東京大学・医・消化器内科

坂本　真樹

岡山大学病院　消化器外科

企画趣旨・ねらい

Recently, emerging evidences suggest that certain commensal bacteria are associated with cancers. Abnormal bacteria and their metabolites affect eithersystemic or local immune responses, which contribute to cancer progression and therapeutic outcomes. Consequently, new approaches that target gut microbiota have been clinically applied to cancer detection and treatment. In this syposium, we will primarily discuss the mechanism how microbiota modulates tumor immunity. We will also discuss recent advances and challenges using microbiota-modulating therapies such as fecal transplantation, prebiotics, or probiotics. We encourage the application and participation of young researchers.

希少がん創薬開発の現状と未来

Live/On Demand9月23日（土）13:30～16:00　第14会場

座長：

眞島　喜幸

日本希少がん患者会ネットワーク

中村　健一

国立がん研セ・中央病院

演者：

大西　啓之

（一社）日本希少がん患者会ネットワーク

飯村　康夫

厚労省・医政

米盛　勧

国立がん研究センター中央病院　腫瘍内科

濱田　哲暢

国立がん研究センター・研・分子薬理

小川　千登世

国立がん研究センター・中央病院小児腫瘍科

大和　隆志

エーザイ株式会社

企画趣旨・ねらい

希少がん、小児がんは製薬企業における開発が必ずしも積極的に行われてこなかった領域であったが、昨今、アカデミアと製薬企業、患者団体が連携して、効率的に薬剤開発を進めようとする取り組みが行われつつある。こうした希少がん、小児がんにおける最新の取り組みについて産学官患のそれぞれの立場から紹介するとともに、グローバルな視点も交えて日本における最適な希少がん創薬開発のあり方についてディスカッションを行う。

薬剤抵抗性機構と耐性克服研究の最前線

Live/On Demand9月23日（土）13:30～16:00　第15会場

座長：

中奥　敬史

国立がん研究セ研・ゲノム生物

片山　量平

（公財）がん研

演者：

中奥　敬史

国立がん研究セ研・ゲノム生物

指宿　立

九州大学大学院医学研究院呼吸器内科学分野

小林　祥久

国立がん研究センター研究所・分子病理分野

衣斐　寛倫

愛知がん・研究所・がん標的治療TR

武川　睦寛

東大・医科研・分子シグナル制御分野

北嶋　俊輔

がん研究会・がん研究所・細胞生物

Chiara Ambrogio

Department of Molecular Biotechnology and Health Sciences

企画趣旨・ねらい

これまでDruggable出なかったKRAS変異陽性のがんに対する分子標的薬、ますます幅広く使用されるようになってきたがん免疫チェックポイント阻害薬などにより、進行がんの予後は急速に改善されつつある。しかし一方で、薬剤耐性による再発が克服すべき課題として未解決のままである。また、治療抵抗性の元には治療残存細胞があり、それらがどのようにして治療抵抗性を獲得しているのかを明らかにしていく必要がある。本セッションでは、今なお課題となっている薬剤耐性について、初期抵抗性、治療残存細胞、獲得耐性に関わる最先端の研究者らが登壇し、治療抵抗性と克服について議論する。

小児がん研究最前線

Live/On Demand9月21日（木）9:00～11:30　第3会場

座長：

滝田　順子

京都大・院医・小児科

加藤　元博

東京大・院医・小児科

演者：

Nita Seibel

National Cancer Institute, National Institutes of Health

高杉　奈緒

東京大学医学部小児科

赤澤　嶺

京都大学大学院 発達小児科学

柳生　茂希

信州大学／京都府立医科大学

寺島　慶太

国立成育医療研究センター・小児がん

Kristopher R. Bosse

Children's Hospital of Philadelphia／Perelman School of Medicine at the University of Pennsylvania

企画趣旨・ねらい

Recent advances in treatment strategies have enabled many patients with pediatric cancers to overcome their disease. However, there are still issues to be resolved, such as intractable disease and late complications in patients who are successfully cured. In other to explore the genetic and epigenetic basis of pediatric cancers and to develop more specific and successful treatment strategies, many researchers have conducted extensive studies on the molecular mechanisms of intractable pediatric malignancies, including leukemia, brain tumors, and neuroblastoma. Throughout these transrational researches in pediatric cancers have led to a better understanding of the molecular pathogenesis of the disease and the development of new diagnostic methods and treatment strategies. In this symposium, cutting-age researches in the field of pediatric cancers will present the latest advances in basic and clinical research directly related to the new therapeutic strategies of pediatric cancers.

肺がん：基礎・TR研究に基づく肺がん新規治療法の可能性

Live/On Demand9月21日（木）13:40～16:10　第4会場

座長：

矢野　聖二

金沢大

後藤　悌

国立がん研究センター中央病院・呼吸器内科

演者：

松本　慎吾

国がんセ東・呼内

長阪　美沙子

University of California Irvine

後藤　悌

国立がん研究センター中央病院・呼吸器内科

田中　謙太郎

九州大学・院・呼吸器内科学

田島　健

順天堂大学大学院医学研究科 呼吸器内科学

片山　量平

（公財）がん研・化療セ・基礎研究部／東大・新領域・メディカル情報生命

企画趣旨・ねらい

進行肺がんの薬物療法は、EGFR活性化変異、さらにはALK融合遺伝子変異をはじめとする様々な融合遺伝子型ドライバーがん遺伝子の発見とそれらの検出手法および分子標的薬の開発により目覚ましい予後の改善が達成されてきた。さらに、がん免疫チェックポイント阻害薬の登場により、肺がん治療はさらなる進化を遂げてきた。さらに、これまでドライバーがん遺伝子が同定されつつも標的治療が登場していなかった一部のKRAS変異やHer2活性化変異陽性肺がんに対する治療法も開発が進んでいる。一方で治療抵抗性による病勢進行が大きな問題として残っている。本セッションでは国内外の基礎・TR・臨床研究者らによる最新の知見を紹介し、今後のさらなる肺がん治療の改善に向けた課題について議論する。

造血器腫瘍研究の最前線

Live/On Demand9月22日（金）9:00～11:30　第8会場

座長：

竹内　賢吾

（公財）がん研・研

片岡　圭亮

慶應・医・血液／国立がんセ・研究所・分子腫瘍

演者：

Ari Melnick

Weill Cornell Medicine: Department of Medicine, Hematology/Oncology

幸谷　愛

東海大学／大阪大学

片岡　圭亮

慶應・医・血液／国立がんセ・研究所・分子腫瘍

藤野　赳至

メモリアル・スローンケタリング癌センター

牧島　秀樹

京大・腫瘍生物学

高橋　康一

テキサス大学MDアンダーソン癌センター

企画趣旨・ねらい

Hematologic malignancies represent a large group of myeloid and lymphoid neoplasms, including leukemia, lymphoma, and myeloma. This is an exciting time in the research of hematologic malignancies, marked by enormous advances in clinical, translational, and basic science. In basic research, a better understanding of the genetic alterations and tumor immune microenvironment has opened new paradigms of elucidating disease pathogenesis and has led to precision oncology in the clinical setting. For example, mapping of clonal heterogeneity of preneoplastic and neoplastic states, including clonal hematopoiesis, has reconstructed the oncogenic trajectories of clonal evolution. The rapid expansion of cutting-edge technologies, such as CRISPRCas9-mediated gene editing, next-generation sequencing, and multimodal single-cell platforms, has largely fueled these advances. These promising advances have inspired not only studies on hematologic malignancies but also research for other cancer types. Indeed, research on hematologic malignancies has pioneered treatments that have been widely adopted, such as targeted therapies, engineered T-cell therapy, and other immunotherapies. In this symposium, we will discuss the recent progress of research on hematologic malignancies, which will lead to a further understanding of cancer biology and genetics, and the improvement of diagnostic and therapeutic strategies in blood cancers.

乳癌・卵巣癌研究の最前線

Live/On Demand9月23日（土）13:30～16:00　第2会場

座長：

山内　英子

University of Hawaii Cancer Center

田代　浩徳

熊本大・院生命・健康科学講座（保健学系）

演者：

西尾　美希

神戸大学大学院医学研究科　分子細胞生物学

後藤　典子

金沢大学・がん進展制御研究所

山内　英子

University of Hawaii Cancer Center

小林　佑介

慶應大・医・産婦人科

増田　健太

慶應義塾大学医学部産婦人科学教室

梶山　広明

名古屋大・医・産婦人科

企画趣旨・ねらい

Although recent breakthroughs in cancer treatment have improved the prognosis for breast cancer patients, breast cancer is the most common cancer in women and the risk of recurrence remains more than 10 years after radical surgery. On the other hands, ovarian cancer is the most lethal cancer of the female reproductive organs, because it is often diagnosed at an advanced stage mainly due to peritoneal dissemination.This symposium will present and discuss the latest research on the development, pathogenesis and treatment strategies of these malignancies. We hope that this symposium will help to improve the prognosis of patients with these cancers.

肝胆膵がんの基礎研究と臨床研究の共闘

Live/On Demand9月23日（土）13:30～16:00　第4会場

座長：

池田　公史

国立がん研セ・東病院

妹尾　浩

京都大・消化器内科

演者：

中川　勇人

三重大学大学院医学系研究科消化器内科学

小笠原　定久

千葉大学大学院医学研究院　消化器内科学

新井　康仁

国立がん研究セ・研・がんゲノミクス

森實　千種

国立がん研究センター中央病院・肝胆膵内科

立石　敬介

聖マリアンナ医科大・医・消化器内科

金井　雅史

京都大学　腫瘍薬物治療学講座

企画趣旨・ねらい

肝胆膵領域の癌は基礎研究の成果に伴い、臨床成績も着実に進歩してきました。細胞障害性抗癌剤に加え、分子標的薬や免疫チェックポイント阻害剤は、いくつかの臨床試験で有効性が示され、precision medicineも日常診療で積極的に行われています。本セッションでは、各癌種におけるprecision medicine、バイオマーカー、免疫微小環境、ドラッグデリバリー、外科研究など基礎と臨床の共闘について解説してもらいます。

脳腫瘍における基礎研究とトランスレーショナルリサーチの最新の知見

Live/On Demand9月23日（土）13:30～16:00　第8会場

座長：

鈴木　啓道

国立がん研セ・研・脳腫瘍連携研究分野

川内　大輔

国立精神・神経医療研究センター

演者：

川内　大輔

国立精神・神経医療研究センター

Haikun Liu

Division of Molecular Neurogenetics, DKFZ

趙　民知

（公財）がん研・研・実験病理部

中島　拓真

国立がん研究センター脳腫瘍連携研究分野／名古屋大学大学院医学系研究科脳神経外科学

Lukas Chavez

SBP Medical Discovery Institute, San Diego／Department of Medicine, UC San Diego／Rady Children's Institue for Genomic Medicine, San Diego

立石　健祐

横浜市大・医・脳神経外科／横浜市大・生命医科学研究科

伊藤　博崇

東大医科研　先端がん治療分野

企画趣旨・ねらい

Malignant brain tumors are highly lethal. Despite recent advances in basic research and clinical management, its prognosis still remains dismal, requiring further comprehensive understanding of this type of disease using multi-layered approaches. Besides, due to a huge inter-tumoral heterogeneity, the personalized medicine is being anticipated based on individual tumor characteristics. Thus, this session focuses on current advances in technologies/platforms for basic and translational research of malignant brain tumors, leading to synergistic acceleration toward establishment of new therapeutic avenues across tumor entities.
Key topic areas that will be addressed include 1) Whole-genome and multi-omics sequencing analysis, 2) Challenges of inter- and intra-tumoral heterogeneity 3) identification of novel and effective biomarkers for diagnosis, monitoring prognosis and treatments and 4) innovative preclinical modeling. The program welcomes early-career investigators and graduate students and calls for abstracts from younger researchers and clinicians.

君にもできるゲノミクス：体細胞変異解析入門1

Live/On Demand9月21日（木）9:00～10:15　第14会場

演者：

上野　敏秀

国立がん研究センター研究所

君にもできるゲノミクス：体細胞変異解析入門2

Live/On Demand9月21日（木）10:15～11:30　第14会場

演者：

上野　敏秀

国立がん研究センター研究所

君にもできる人工知能：Pythonプログラミングに必要なこと

Live/On Demand9月22日（金）9:00～10:15　第14会場

演者：

辻　真吾

東京大学先端科学技術研究センター

君にもできるエピゲノム解析：はじめてのがんエピゲノム解析

Live/On Demand9月22日（金）10:15～11:30　第14会場

演者：

田中　庸介

国立がん研究センター研究所

君にもできるゲノミクス：RNA-seq解析入門

Live/On Demand9月23日（土）9:00～10:15　第14会場

演者：

小島　進也

国立がん研究センター研究所

君にもできる一細胞解析

Live/On Demand9月23日（土）10:15～11:30　第14会場

演者：

入江　拓麿

国立がん研究センター・EPOC・免疫TR分野

Year in review: 免疫チェックポイント阻害治療における代謝制御の新展開

Live/On Demand9月22日（金）7:50～8:40　第2会場

演者：

茶本　健司

京大・医・がん免疫PDT／京大・医・がん免疫セ・免疫ゲノム

Year in review: 腸内細菌とがん

Live/On Demand9月22日（金）7:50～8:40　第3会場

演者：

谷内田　真一

大阪大・医・がんゲノム情報学

Year in review: インパクトを与えた臨床試験

Live/On Demand9月22日（金）7:50～8:40　第4会場

演者：

勝屋　友幾

国立がん研究センター中央病院　先端医療科

Year in review: 全ゲノム解析の医療実装

Live/On Demand9月22日（金）7:50～8:40　第5会場

演者：

角南　久仁子

国立がん研セ・中央病院・臨床検査科

がんと相分離・スーパーエンハンサー

Live/On Demand9月22日（金）7:50～8:40　第8会場

演者：

芳野　聖子

名古屋大学・医院・分子腫瘍学

医療情報の標準化の動向とがん研究領域での利活用

Live/On Demand9月22日（金）7:50～8:40　第11会場

演者：

土井　俊祐

千葉大・医学部附属病院・企画情報部

論理的かつ魅力ある英文科学論文を書くために

Live/On Demand9月22日（金）7:50～8:40　第14会場

演者：

中釜　斉

国立がん研

空間トランスクリプトーム解析を駆使したがん研究の実際：実験から情報解析まで

Live/On Demand9月22日（金）7:50～8:40　第15会場

演者：

鈴木　絢子

東大・新領域

Year in review: 2023年の免疫チェックポイント阻害剤奏功に関するトランスレーショナル研究

Live/On Demand9月22日（金）7:50～8:40　第16会場

演者：

熊谷　尚悟

国立がん研究センター　免疫TR分野

細胞老化を標的とした先進的な健康寿命延伸法の創出を目指して

Live/On Demand9月22日（金）7:50～8:40　第17会場

演者：

城村　由和

金沢大学　がん進展制御研究所／金沢大学　新学術創成研究機構

日本人のがん患者5万例のリアルワールドデータ(C-CATデータ)を使って研究しませんか？

Live/On Demand9月23日（土）7:50～8:40　第2会場

演者：

河野　隆志

国立がん研究セ・C-CAT

Year in review: RNAとがん

Live/On Demand9月23日（土）7:50～8:40　第3会場

演者：

井上　大地

神戸先端研・血液・腫瘍研究部

Year in review: 分子標的薬耐性の分子機構とその克服

Live/On Demand9月23日（土）7:50～8:40　第4会場

演者：

衣斐　寛倫

愛知がん・研究所・がん標的治療TR

Year in review: ADC製剤の最近の動向

Live/On Demand9月23日（土）7:50～8:40　第5会場

講師：

佐藤　潤

国立がん研究センター中央病院・先端医療

発がんの自然史

Live/On Demand9月23日（土）7:50～8:40　第8会場

講師：

垣内　伸之

京都大学白眉センター／京都大学大学院医学研究科消化器内科学

セレブロン制御

Live/On Demand9月23日（土）7:50～8:40　第11会場

講師：

伊藤　拓水

東京医大・医総研／東大・薬・TPD

CRISPR-KOスクリーニングの開発と応用

Live/On Demand9月23日（土）7:50～8:40　第14会場

講師：

遊佐　宏介

京都大・医生研

深層学習技術による一細胞・空間オミクスの解析

Live/On Demand9月23日（土）7:50～8:40　第15会場

講師：

小嶋　泰弘

国立がん研究センター　計算生命ユニット／東京医科歯科　難研　計算システム

Year in review: がん免疫細胞療法開発の最新動向

Live/On Demand9月23日（土）7:50～8:40　第16会場

講師：

渡邊　慶介

国立がん研究センター　腫瘍免疫研究分野

Year in review: がんのウイルス療法

Live/On Demand9月23日（土）7:50～8:40　第17会場

講師：

藤堂　具紀

東大・医科研・先端がん治療